SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Jun-Ying Liu, Yun-Jian Sheng, Xiang-Chun Ding, Hui Tang, Shi-Wen Tong, Da-Zhi Zhang, Zhi Zhou, Peng Hu, Yong Liao, Hong Ren, Huai-Dong Hu, The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: A meta-analysis, Journal of the Formosan Medical Association, 2015, 114, 2, 164

    CrossRef

  2. 2
    Gui-Nan Lin, Jie-Wen Peng, Jian-jun Xiao, Dong-Ying Liu, Zhong-Jun Xia, Hepatitis B virus reactivation in hepatitis B surface antigen seropositive patients with metastatic non-small cell lung cancer receiving cytotoxic chemotherapy: the efficacy of preemptive lamivudine and identification of risk factors, Medical Oncology, 2014, 31, 8

    CrossRef

  3. 3
    Hyun Jung Lee, Dae Young Kim, Bhumsuk Keam, Jeong Hoon Lee, Sae-Won Han, Do-Youn Oh, Jung Hwan Yoon, Tae-You Kim, Yu Jung Kim, Keun Wook Lee, Jin-Wook Kim, Sook-Hyang Jeong, Jong Seok Lee, Jee Hyun Kim, Seock-Ah Im, Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy, Breast Cancer, 2014, 21, 4, 387

    CrossRef

  4. 4
    Ya-Wen Yang, Chih-Yuan Lee, Rey-Heng Hu, Po-Huang Lee, Meng-Kun Tsai, Long-term effects of prophylactic and therapeutic lamivudine treatments in hepatitis B surface antigen-positive renal allograft recipients, Clinical and Experimental Nephrology, 2014, 18, 1, 144

    CrossRef

  5. 5
    Xiang-Yuan Wu, Xing Li, Zhan-Hong Chen, Jing-Yun Wen, Qu Lin, Yan-Fang Xing, Min Dong, Li Wei, Tian-Tian Wang, Jie Chen, Ze-Xiao Lin, Xiang-bo Wan, Dan-Yun Ruan, Xiao-Kun Ma, An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study, Tumor Biology, 2013, 34, 2, 909

    CrossRef

  6. 6
    Mario Mandalà, Stefano Fagiuoli, Daniela Francisci, Raffaele Bruno, Barbara Merelli, Luisa Pasulo, Carlo Tondini, Roberto Labianca, Fausto Roila, Hepatitis B in immunosuppressed cancer patients: Pathogenesis, incidence and prophylaxis, Critical Reviews in Oncology/Hematology, 2013, 87, 1, 12

    CrossRef

  7. 7
    Yoshimi Ide, Yoshinori Ito, Shunji Takahashi, Nahomi Tokudome, Kokoro Kobayashi, Tsutomu Sugihara, Masaya Hattori, Masahiro Yokoyama, Akira Uchiyama, Kazuaki Inoue, Norio Sakurai, Kiyohiko Hatake, Hepatitis B virus reactivation in adjuvant chemotherapy for breast cancer, Breast Cancer, 2013, 20, 4, 367

    CrossRef

  8. 8
    Chun-Jen Liu, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao, Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management, Hepatology International, 2013, 7, 2, 316

    CrossRef

  9. 9
    W H Y Ling, P P Soe, A S L Pang, S-C Lee, Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours, British Journal of Cancer, 2013, 108, 10, 1931

    CrossRef

  10. 10
    Gang Huang, Eric C. H. Lai, Wan Yee Lau, Wei-ping Zhou, Feng Shen, Ze-ya Pan, Si-yuan Fu, Meng-chao Wu, Posthepatectomy HBV Reactivation in Hepatitis B–Related Hepatocellular Carcinoma Influences Postoperative Survival in Patients With Preoperative Low HBV-DNA Levels, Annals of Surgery, 2013, 257, 3, 490

    CrossRef

  11. 11
    Yihu Zheng, Shengchu Zhang, Hooi Min Tan Grahn, Chao Ye, Zheng Gong, Qiyu Zhang, Prophylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis, Hepatitis Monthly, 2013, 13, 4

    CrossRef

  12. 12
    Alexander Kuo, Robert Gish, Chronic Hepatitis B Infection, Clinics in Liver Disease, 2012, 16, 2, 347

    CrossRef

  13. 13
    KASL Clinical Practice Guidelines: Management of chronic hepatitis B, Clinical and Molecular Hepatology, 2012, 18, 2, 109

    CrossRef

  14. 14
    Jeong Won Jang, Management of Patients with Hepatitis B Virus Infection Who Receive Immunosuppressive Treatment or Chemotherapy, Korean Journal of Medicine, 2012, 82, 2, 149

    CrossRef

  15. 15
    Makoto Oketani, Akio Ido, Hirofumi Uto, Hirohito Tsubouchi, Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy, Hepatology Research, 2012, 42, 7
  16. 16
    Amanda Abramson, Alan Menter, Robert Perrillo, Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management, Journal of the American Academy of Dermatology, 2012, 67, 6, 1349

    CrossRef

  17. 17
    Harrys A. Torres, Marta Davila, Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer, Nature Reviews Clinical Oncology, 2012, 9, 3, 156

    CrossRef

  18. 18
    Meijun Long, Weijuan Jia, Shunrong Li, Liang Jin, Jiannan Wu, Nanyan Rao, Huiyi Feng, Kai Chen, Heran Deng, Fengtao Liu, Fengxi Su, Erwei Song, A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?, Breast Cancer Research and Treatment, 2011, 127, 3, 705

    CrossRef

  19. 19
    Pil Soo Sung, Si Hyun Bae, Jeong Won Jang, Do Seon Song, Hee Yeon Kim, Sun Hong Yoo, Chung-Hwa Park, Jung Hyun Kwon, Myeong Jun Song, Chan Ran You, Jong Young Choi, Seung Kew Yoon, Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization, The Korean Journal of Hepatology, 2011, 17, 4, 299

    CrossRef

  20. 20
    Ramazan Idilman, Mutlu Arat, Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation, Expert Review of Anti-infective Therapy, 2011, 9, 8, 641

    CrossRef

  21. 21
    Kalliopi Zachou, George N. Dalekos, Hepatitis B re-activation with rituximab therapy: treat the patient not the disease, Liver International, 2011, 31, 3
  22. 22
    Cheng-Yuan Peng, Chih-Bin Chen, Hsueh-Chou Lai, Wen-Pang Su, Po-Heng Chuang, Hong-Dar Isaac Wu, Long-Bin Jeng, Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation, Hepatology International, 2011, 5, 1, 586

    CrossRef

  23. 23
    Shih-Hung Tsai, Ming-Shen Dai, Jyh-Cherng Yu, Ching-Liang Ho, Yeu-Chin Chen, Yi-Ying Wu, Ping-Ying Chang, Woei-Yau Kao, Tsu-Yi Chao, Preventing chemotherapy-induced hepatitis B reactivation in breast cancer patients: a prospective comparison of prophylactic versus deferred preemptive lamivudine, Supportive Care in Cancer, 2011, 19, 11, 1779

    CrossRef

  24. 24
    B. S. Sohn, J. H. Ahn, K. H. Jung, S.-H. Ahn, B. H. Son, G. Gong, S.-B. Kim, Updated Longitudinal Data on Acute Exacerbation of Chronic Hepatitis B in Patients With Breast Cancer Receiving Anthracycline-based Adjuvant Chemotherapy: Therapeutic vs. Pre-emptive Use of Lamivudine, Japanese Journal of Clinical Oncology, 2011, 41, 9, 1059

    CrossRef

  25. 25
    Masaaki Watanabe, Akitaka Shibuya, Juichi Takada, Yoshiaki Tanaka, Yusuke Okuwaki, Tsutomu Minamino, Hisashi Hidaka, Takahide Nakazawa, Wasaburo Koizumi, Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: A review of 16 patients, European Journal of Internal Medicine, 2010, 21, 4, 333

    CrossRef

  26. You have free access to this content26
    John S Lubel, Peter W Angus, Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: Diagnosis and management, Journal of Gastroenterology and Hepatology, 2010, 25, 5
  27. 27
    Yutaka Tsutsumi, Reiki Ogasawara, Yusuke Kamihara, Shinichi Ito, Yoshiya Yamamoto, Junji Tanaka, Masahiro Asaka, Masahiro Imamura, Rituximab Administration and Reactivation of HBV, Hepatitis Research and Treatment, 2010, 2010, 1

    CrossRef

  28. 28
    Orhan Onder Eren, Mehmet Artac, Melih Cem Boruban, Ozlem Yavas, Ugur Arslan, Metin Basaranoglu, Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience, Medical Oncology, 2009, 26, 4, 386

    CrossRef

  29. 29
    Yutaka Tsutsumi, Yoshiya Yamamoto, Junji Tanaka, Masahiro Asaka, Masahiro Imamura, Nobuo Masauzi, Prevention of hepatitis B virus reactivation under rituximab therapy, Immunotherapy, 2009, 1, 6, 1053

    CrossRef

  30. 30
    Tara N. Palmore, Neeral L. Shah, Rohit Loomba, Brian B. Borg, Uri Lopatin, Jordan J. Feld, Farooq Khokhar, Glen Lutchman, David E. Kleiner, Neal S. Young, Richard Childs, A. John Barrett, T. Jake Liang, Jay H. Hoofnagle, Theo Heller, Reactivation of Hepatitis B With Reappearance of Hepatitis B Surface Antigen After Chemotherapy and Immunosuppression, Clinical Gastroenterology and Hepatology, 2009, 7, 10, 1130

    CrossRef

  31. 31
    Yong Yuan, Uchenna Iloeje, Hong Li, Joel Hay, Guang B. Yao, Economic Implications of Entecavir Treatment in Suppressing Viral Replication in Chronic Hepatitis B (CHB) Patients in China from a Perspective of the Chinese Social Security Program, Value in Health, 2008, 11,
  32. 32
    L. H. Katz, A. Fraser, A. Gafter-Gvili, L. Leibovici, R. Tur-Kaspa, Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis, Journal of Viral Hepatitis, 2008, 15, 2
  33. 33
    Lenna A. Martyak, Ehsan Taqavi, Sammy Saab, Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis, Liver International, 2008, 28, 1
  34. 34
    Roberto J. Firpi, David R. Nelson, Management of viral hepatitis in hematologic malignancies, Blood Reviews, 2008, 22, 3, 117

    CrossRef

  35. 35
    Ali Amouri, Lassaad Chtourou, Leila Mnif, Nabi Tahri, Prise en charge de la réactivation virale B au cours d’un traitement chimiothérapique ou immunosuppresseur, La Presse Médicale, 2008, 37, 11, 1591

    CrossRef

  36. 36
    Holbrook E. Kohrt, Daniel L. Ouyang, Emmet B. Keeffe, Antiviral Prophylaxis for Chemotherapy-Induced Reactivation of Chronic Hepatitis B Virus Infection, Clinics in Liver Disease, 2007, 11, 4, 965

    CrossRef

  37. 37
    Sammy Saab, Mamie H. Dong, Tom A. Joseph, Myron J. Tong, Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: A decision analysis model, Hepatology, 2007, 46, 4
  38. 38
    J. S. Lubel, A. G. Testro, P. W. Angus, Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management, Internal Medicine Journal, 2007, 37, 10
  39. 39
    Jeong Won Jang, Jong Young Choi, Si Hyun Bae, Seung Kew Yoon, U Im Chang, Chang Wook Kim, Se Hyun Cho, Jun Yeol Han, Young Sok Lee, A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization, Hepatology, 2006, 43, 2
  40. 40
    Winnie Yeo, Philip J. Johnson, Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy, Hepatology, 2006, 43, 2
  41. 41
    Annarosa Floreani, Sara Boninsegna, Salvatore Lobello, Diego Caroli, Stefano Fagiuoli, Fatal hepatic decompensation in a bone marrow transplant recipient with HBV-related cirrhosis following lamivudine withdrawal, Gastroentérologie Clinique et Biologique, 2006, 30, 2, 307

    CrossRef

  42. 42
    H. E. KOHRT, D. L. OUYANG, E. B. KEEFFE, Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection, Alimentary Pharmacology & Therapeutics, 2006, 24, 7
  43. 43
    Ming-Shen Dai, Tsu-Yi Chao, Lamivudine therapy in HBsAg-carrying breast cancer patients undergoing chemotherapy: prophylactic or preemptive?, Breast Cancer Research and Treatment, 2005, 92, 1, 95

    CrossRef